Subjects who consumed cannabis were less likely than non-users to suffer from symptoms of sinonasal diseases
Cannabis consumers are far less likely than non-users to develop chronic rhinitis and similar sinonasal diseases, according to case-control data published in the journal Laryngoscope Investigative Otolaryngology.
Researchers affiliated with Houston’s Methodist Hospital, Department of Otolaryngology, assessed rates of chronic rhinosinusitis (CRS), allergic rhinitis (AR), and chronic rhinitis (CR) in a nationally representative sample of 25,164 cannabis consumers and 113,418 matched controls.
Contrary to investigators’ expectations, subjects who consumed cannabis were less likely than non-users to suffer from symptoms of sinonasal diseases, with more frequent consumers possessing the lowest risk. This inverse relationship persisted regardless of whether subjects smoked cannabis or orally ingested marijuana products.
“Given the known detrimental impact of tobacco smoking use on sinonasal tissue and inflammation, it was expected that patients who more regularly used cannabis would also be more likely to have sinonasal inflammatory diseases, especially in those who smoked cannabis.
However, the present study results do not support this hypothesis,” the study’s authors concluded. “Instead, … certain user cohorts were almost half as likely to develop CRS, AR, and CR as never users. … To our knowledge, this is the first study to demonstrate this finding.”
Sinonasal diseases are characterized by persistent inflammation of the nasal passages. They are estimated to adversely impact the health of approximately one-quarter of the global population.
This brief was republished from NORML. Full text of the study, “The associative impact of recreational cannabis on sinonasal diseases,” appears in Laryngoscope Investigative Otolaryngology.
